# HRTX — Heron Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** HRTX  
**Sources:** 18  
**Published:** 2026-08-14  
**Canonical:** https://app.k3vl4r.com/research/deep-research-hrtx-heron-therapeutics-inc-catalysts-narrative-risks-2035

---

# Heron Therapeutics Inc (HRTX) — Research Summary as of August 14, 2026

## Company Overview

Heron Therapeutics is a commercial-stage biotechnology company focused on acute care therapeutics. Its product portfolio includes **ZYNRELEF** (a dual-acting local anesthetic), **APONVIE**, **CINVANTI**, and **SUSTOL** [[8]](https://www.marketscreener.com/news/heron-therapeutics-announces-first-quarter-2026-financial-results-and-reaffirms-guidance-ce7f5bd8d08af025).

---

## Key Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-hrtx-heron-therapeutics-inc-catalysts-narrative-risks-2035 (free to sign up)._